Profits In A Year Of Transition: Novartis India Posts ₹90.5 Crore Revenue And ₹25.25 Crore Profit For March Quarter

Novartis India Limited (NSE: NOVARTIND) declared its Q4 FY26 results today, May 12, 2026, with the board convened specifically to review the financials for the quarter and year ended March 31, 2026. The quarter carries unusual weight  it is almost certainly the last set of results filed under Novartis AG's promotership. In Q3 FY26, the company had posted a net profit of ₹16.09 crore on revenue from operations of ₹85.90 crore, with both metrics declining sharply year-on-year. The Q4 numbers represent a tangible sequential recovery.

A Quarter Of Recovery

Revenue from operations for the March quarter came in at ₹90.55 crore and net profit at ₹25.25 crore. This compares favourably to Q3 FY26's ₹85.90 crore in revenue and ₹16.09 crore in profit  a quarter-on-quarter improvement on both lines. For the full year FY2024-25, Novartis India had reported revenue from operations of ₹356.27 crore and profit after tax of ₹100.90 crore. The Q4 FY26 earnings give the company a solid exit point for a fiscal year defined more by ownership change than operations.

The Ownership Overhaul In Progress

The result arrives amid a landmark corporate transition. Swiss drugmaker Novartis AG has signed a share purchase agreement with a ChrysCapital-led consortium comprising WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners to transfer its 70.68% shareholding in Novartis India Limited for approximately ₹1,446 crore, marking its complete exit from the listed Indian entity.

Under SEBI takeover regulations, the acquisition triggered a mandatory open offer to public shareholders to acquire up to 26% at ₹860.64 per share, with a potential further outlay of up to ₹552.49 crore if fully subscribed. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary conditions.

What Happens To The Novartis Brand In India

Novartis India has undertaken to change its name to remove all references to the Novartis AG group within 120 days from the completion of the transaction. Novartis AG clarified that the stake sale will not affect the operations of Novartis Healthcare Private Limited, its wholly owned subsidiary, which will continue its commercial and R&D operations in India independently.

Novartis India has maintained a healthy dividend payout of 82.3% of profits over the past several years and has delivered profit growth of 58.5% CAGR over the last five years  a record that its new owners at ChrysCapital will inherit along with a business now poised for a fresh strategic chapter.

Key Highlights

• Q4 FY26 revenue from operations at ₹90.55 crore, up sequentially from Q3's ₹85.90 crore
• Q4 FY26 net profit at ₹25.25 crore, a sharp recovery from Q3's ₹16.09 crore
• Board met on May 12, 2026 to approve audited Q4 and full-year FY26 financial results
• Novartis AG has agreed to sell its 70.68% stake to a ChrysCapital-led consortium for ₹1,446 crore
• Mandatory open offer to public shareholders at ₹860.64 per share for up to 26% of voting capital
• Transaction closure expected in Q3 2026 pending regulatory approvals
• Company name to be changed within 120 days of deal completion, removing Novartis AG branding
• Novartis Healthcare Private Limited's India operations remain unaffected by the stake sale
• Five-year profit CAGR of 58.5% reflects the underlying earnings strength of the listed entity

Sources: NSE/BSE Exchange Filing, Business Today, Business Standard, Outlook Business, Bloomberg, Screener.in, Tickertape